Welcome to our dedicated page for Inhibrx Biosciences SEC filings (Ticker: INBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibrx Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company with two principal clinical programs, ozekibart (INBRX-109) and INBRX-106. Form 8-K reports furnish financial results, Regulation FD presentations, and clinical updates covering oncology studies in chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
The company’s proxy materials describe annual meeting matters, board elections, executive compensation and equity incentive governance. Its filings also identify Inhibrx Biosciences as an emerging growth company and provide formal disclosures on operating results, pipeline development, capital resources, risk factors, and the completed 2024 separation from Inhibrx, Inc.
Inhibrx Biosciences, Inc. Schedule 13G/A amendment reports beneficial ownership by Viking Global affiliated entities and related persons and removes David C. Ott as a reporting person effective March 31, 2026. The filing lists aggregate beneficial ownership positions and discloses a Warrant exercise limiter (the "Blocker").
The filing states that Viking Global Investors LP and affiliated entities may be deemed to beneficially own up to 1,461,633 shares (representing 9.99% of the class) based on 14,607,036 shares outstanding as of March 11, 2026, and details component holdings among VGOP, KAVRA 104, VGOD and related GPs.
INHIBRx Biosciences filed an amendment to a Schedule 13G/A reporting shared beneficial ownership of 1,461,105 shares, equal to 9.99% of common stock. The filing states there were 14,607,286 shares outstanding as of April 7, 2026 and that the Reporting Persons assume exercise of Pre-Funded Warrants for 18,398 shares when calculating ownership. The Master Fund directly holds 1,442,707 shares and 732,157 pre-funded warrants exercisable at $0.0001 per share, subject to a Beneficial Ownership Limitation that caps aggregate exercises to not more than 9.99%. Perceptive Advisors is the investment manager and Joseph Edelman is the managing member; both are reported as beneficial owners by attribution.
Inhibrx Biosciences, Inc. reported first quarter 2026 results, showing a narrower net loss and a stronger cash position alongside higher debt and a stockholders’ deficit. Net loss was $33.4 million, or $2.15 per share, compared to $43.3 million, or $2.80 per share, in the first quarter of 2025.
Research and development expenses fell to $25.2 million, and general and administrative costs were broadly stable at $5.7 million. Cash and cash equivalents rose to $161.7 million as of March 31, 2026, supported by $75.0 million of additional loan proceeds, which increased long-term debt to $175.0 million and resulted in a stockholders’ deficit of $21.0 million.
Clinically, the company highlighted updated interim data for INBRX-106 in a randomized Phase 2 HNSCC trial and for ozekibart (INBRX-109) in colorectal cancer. It submitted a Biologics License Application for ozekibart in conventional chondrosarcoma and plans key FDA interactions in the second half of 2026.
Inhibrx Biosciences reported a Q1 2026 net loss of $33.4M, narrowing from $43.3M a year earlier as operating expenses fell. Research and development dropped 32% to $25.2M, mainly from lower chondrosarcoma trial and manufacturing costs, while general and administrative expense was $5.7M.
Cash and cash equivalents were $161.7M as of March 31, 2026, and management believes this will fund operations for at least 12 months, but long‑term debt rose to $175.0M after drawing an additional $75.0M term loan at an effective interest rate of 17.5%.
The pipeline advanced meaningfully. Ozekibart showed encouraging efficacy in colorectal cancer and Ewing sarcoma and has a biologics license application filed for conventional chondrosarcoma after a registrational trial more than doubled median progression‑free survival to 5.52 months. INBRX‑106 delivered higher response rates than pembrolizumab alone in first‑line head and neck cancer, with a Phase 3 HexAgon study planned to start in the third quarter of 2026.
Inhibrx Biosciences reported encouraging interim Phase 2 data for INBRX-106 in first-line head and neck squamous cell carcinoma with high PD-L1 expression. In the evaluable population, INBRX-106 plus pembrolizumab achieved a confirmed objective response rate of 44.0% (11 of 25 patients) versus 21.4% (6 of 28) with pembrolizumab alone, a 22.6% absolute improvement, including three complete responses in the combination arm and none in the control arm.
Pharmacodynamic analyses showed up to a 15-fold increase in CD8+ and CD4+ T‑cell proliferation and up to a four-fold increase in activation with the combination, compared with up to 2.5-fold and 1.5-fold increases on pembrolizumab alone. The safety profile of INBRX-106 plus pembrolizumab was generally manageable, with mostly low‑grade rash, diarrhea, fatigue and infusion reactions and no treatment-related deaths.
The company plans to start the Phase 3 portion of the HexAgon study in third-quarter 2026 and expects progression‑free survival data from Phase 2 in fourth-quarter 2026. Inhibrx also outlines expansion plans for INBRX-106 into perioperative and front‑line metastatic non‑small cell lung cancer and other checkpoint‑inhibitor‑sensitive tumors, estimating a potential addressable market of about $50 billion if the drug ultimately extends across major PD‑1/PD‑L1 indications.
Inhibrx Biosciences, Inc. reported that President David Matly received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $129.06 per share and expire on April 24, 2036.
According to the vesting terms, 25% of the options become exercisable on April 24, 2027, with the remaining shares vesting in equal monthly installments over the next 36 months, subject to his continuous service with the company. Following this award, he holds 50,000 stock options directly.
Inhibrx Biosciences, Inc. is asking stockholders to vote at its virtual-only 2026 Annual Meeting on June 3, 2026. Stockholders will elect two Class II directors, Douglas G. Forsyth and Kimberly Manhard, to serve until 2029 and ratify BDO USA, P.C. as independent auditor for 2026.
The record date is April 7, 2026, when 14,607,286 common shares were outstanding and entitled to one vote each. The proxy also details board structure, committee memberships, director pay, and executive compensation, including 2025 total pay of $2,892,473 for CEO Mark P. Lappe, $923,696 for CFO Kelly D. Deck, and $1,435,940 for President David J. Matly.
Inhibrx Biosciences, Inc. reported updated interim results from its Phase 1/2 trial of ozekibart (INBRX-109) plus FOLFIRI in heavily pretreated colorectal cancer. Among 45 evaluable patients, objective response rate was 20% per RECIST v1.1, versus historical standards of care with 1–6% response rates, and nearly half of responses lasted more than six months.
Median progression-free survival was 5.5 months, with 42% of patients progression-free at six months and an overall disease control rate of 87%. Safety remained manageable, with mostly Grade 1–2 diarrhea, fatigue and nausea and no significant liver toxicity despite 68% of patients having baseline liver metastases.
Inhibrx plans to meet the FDA in the second half of 2026 about a first-line registrational colorectal cancer trial and possible accelerated pathways in fourth-line colorectal cancer and refractory Ewing sarcoma. The company also submitted a BLA for ozekibart in conventional chondrosarcoma in April 2026.
Inhibrx Biosciences, Inc. reported fourth quarter and full-year 2025 results and outlined key 2026 clinical milestones. The company is now focused on two clinical programs, ozekibart (INBRX-109) and INBRX-106, following the prior sale of INBRX-101 and spin-off from its former parent.
For 2025, Inhibrx recorded a net loss of $140.1 million, or $9.04 per share, compared with net income of $1.7 billion in 2024, which had included a large one-time gain from the 101 Transaction. Research and development expenses fell to $113.0 million from $203.7 million, while general and administrative expenses declined to $23.3 million from $127.9 million as transaction- and litigation-related costs rolled off.
As of December 31, 2025, cash and cash equivalents were $124.2 million. On March 18, 2026, the company amended its loan agreement with Oxford Finance and received gross proceeds of $75.0 million. Inhibrx expects to submit a BLA for ozekibart in early Q2 2026 and to report multiple ozekibart and INBRX-106 data readouts through 2026.